NEW YORK ( TheStreet) -- CHANGE IN RATINGS
Accretive Health (AH - Get Report) initiated at Credit Suisse with an Outperform rating and $17 price target. The company is well-positioned to benefit from the positive long-term trends in the revenue cycle industry, Credit Suisse said.Accretive Health (AH - Get Report) was initiated with a Neutral rating at Robert Baird. $15 price target. Akamai Technologies (AKAM - Get Report) downgraded from Buy to Neutral at Merriman, Curhan Ford. Valuation call, as the stock is up 80% year-to-date. Ameriprise Financial (AMP - Get Report) was upgraded from Hold to Buy at Citigroup. $50 price target. Estimates also boosted, as the company should be able to successfully integrate the Columbia acquisition. AthenaHealth (ATHN) initiated at JP Morgan with a Neutral rating and $34 price target. 2010 EPS estimates of 49 cents. Bristol-Myers (BMY - Get Report) was initiated with a Hold rating at Soleil Securities. $28 price target. Company has a promising pipeline, but already trades at a premium valuation. Berkshire Hathaway (BRK.B - Get Report) was initiated with a Buy rating at Goldman Sachs. Intrinsic value of the stock is up around $101, and the company is leveraged to a cyclical economic recovery. Covidien (COV) was downgraded from Buy to Neutral at Goldman Sachs. $48 price target. Estimates also cut, as merger-and-acquisition dilution and currency should weigh on earnings. Walt Disney (DIS) was upgraded to Buy at Goldman Sachs. $42 price target. Company has a strong film slate and parks pricing appears to be recovering. Genworth Financial (GNW) was upgraded from Equal-weight to Overweight at Morgan Stanley. $20 price target. Improving mortgage insurance results should help drive growth. KBR (KBR) was initiated with a Buy rating at Sterne Agee. $28 price target. Company could see a higher multiple, with backlog quality improving. Eli Lilly (LLY) was initiated with a Sell rating at Soleil Securities. $28 price target. Company will have several products coming off patent soon. MedAssets (MDAS) was initiated with a neutral rating and $32 price target at JP Morgan. 2010 EPS estimates of 91 cents.